HealthDay News — Patients with diabetes report worse quality of life (QoL) with more intensified treatment, according to a study published in online in Diabetes Care.
Clare Bradley, PhD, from the University of London, and colleagues assessed predictors (patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin) for patient-reported outcome measures (PROMs) among 5813 patients with type 2 diabetes.
The researchers found that mean PROM scores indicated that QoL was “good.” Patient-reported treatment satisfaction exceeded physicians’ estimates. Worse QoL was predicted by intensifying treatments to 3 oral agents or insulin regimens (P <.01).
Use of insulin alone also predicted worse QoL (P <.02), as did hypoglycemia worry (P <.007). There were no significant associations between any treatment and EuroQoL-5 Dimension visual analogue scale health status.
“The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Bristol-Myers Squibb, both of which funded the trial.
Bradley C, Eschwège E, de Pablos-Velasco P, et al. Predictors of quality of life and other patient-reported outcomes in the PANORAMA multinational study of people with type 2 diabetes [published online November 28, 2017]. Diabetes Care. doi: 10.2337/dc16-2655